Acumen Pharmaceuticals (ABOS) Expected to Announce Quarterly Earnings on Tuesday

Acumen Pharmaceuticals (NASDAQ:ABOS - Get Free Report) will likely be issuing its Q1 2025 quarterly earnings data before the market opens on Tuesday, May 13th. Analysts expect the company to announce earnings of ($0.94) per share for the quarter.

Acumen Pharmaceuticals (NASDAQ:ABOS - Get Free Report) last posted its quarterly earnings results on Thursday, March 27th. The company reported ($0.62) earnings per share for the quarter, missing analysts' consensus estimates of ($0.47) by ($0.15). On average, analysts expect Acumen Pharmaceuticals to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Acumen Pharmaceuticals Stock Down 2.0 %

ABOS traded down $0.02 during midday trading on Friday, hitting $0.98. 129,655 shares of the company's stock traded hands, compared to its average volume of 291,444. The company has a debt-to-equity ratio of 0.14, a current ratio of 10.43 and a quick ratio of 10.43. The company has a market cap of $59.37 million, a PE ratio of -0.71 and a beta of 0.09. Acumen Pharmaceuticals has a one year low of $0.86 and a one year high of $3.92. The stock's fifty day simple moving average is $1.10 and its 200-day simple moving average is $1.67.

Analysts Set New Price Targets

ABOS has been the topic of several analyst reports. HC Wainwright lowered their target price on shares of Acumen Pharmaceuticals from $15.00 to $11.00 and set a "buy" rating on the stock in a research report on Friday, March 28th. UBS Group cut their price objective on Acumen Pharmaceuticals from $6.00 to $4.00 and set a "buy" rating on the stock in a research note on Friday, March 28th.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers.